Clinical Trial Update: Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Brigatinib plus Bevacizumab in ALK-rearranged non-small cell lung cancer (locally advanced to metastatic/recurrent). The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)
• Avastin (bevacizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING